Serum sclerostin concentration reflects bone turnover and glycation in men with type 2 diabetes mellitus
Objective: The risk of fracture is higher in people with than without diabetes. Because bone mineral density is not a good predictive marker of bone strength in people with diabetes, another surrogate is needed. Sclerostin is an inhibitor of bone formation and is secreted mainly by osteocytes. This...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Fujita Medical Society
2018-02-01
|
| Series: | Fujita Medical Journal |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/fmj/4/1/4_2017006/_pdf/-char/en |
| _version_ | 1818217047482433536 |
|---|---|
| author | Eisuke Tomatsu Megumi Shibata Yasumasa Yoshino Sahoko Sekiguchi-Ueda Ayako Kakita Takeshi Takayanagi Masaki Makino Nobuki Hayakawa Atsushi Suzuki |
| author_facet | Eisuke Tomatsu Megumi Shibata Yasumasa Yoshino Sahoko Sekiguchi-Ueda Ayako Kakita Takeshi Takayanagi Masaki Makino Nobuki Hayakawa Atsushi Suzuki |
| author_sort | Eisuke Tomatsu |
| collection | DOAJ |
| description | Objective: The risk of fracture is higher in people with than without diabetes. Because bone mineral density is not a good predictive marker of bone strength in people with diabetes, another surrogate is needed. Sclerostin is an inhibitor of bone formation and is secreted mainly by osteocytes. This study was performed to clarify how the serum sclerostin concentration reflects bone turnover in patients with type 2 diabetes. Methods: We measured the serum sclerostin concentration and other bone turnover markers in 49 patients with type 2 diabetes (26 men and 23 postmenopausal women). The osteo-sono assessment index was measured using ultrasonography at the calcaneus. Results: In men, the serum sclerostin concentration was significantly correlated with age, homocysteine, and pentosidine, reflecting an accumulation of advanced glycation end products in the bone. The multiple regression analysis showed that the serum pentosidine concentration was associated with the serum sclerostin concentration in men with type 2 diabetes. In contrast, sclerostin was not significantly correlated with pentosidine or other bone turnover markers in women with type 2 diabetes. Conclusions: The serum sclerostin concentration seems to increase in accordance with the accumulation of advanced glycation end products in patients with type 2 diabetes and might reflect the bone quality in men with diabetes. |
| first_indexed | 2024-12-12T07:01:39Z |
| format | Article |
| id | doaj.art-1b45dbb520a041cc8feb9e65497961bf |
| institution | Directory Open Access Journal |
| issn | 2189-7247 2189-7255 |
| language | English |
| last_indexed | 2024-12-12T07:01:39Z |
| publishDate | 2018-02-01 |
| publisher | Fujita Medical Society |
| record_format | Article |
| series | Fujita Medical Journal |
| spelling | doaj.art-1b45dbb520a041cc8feb9e65497961bf2022-12-22T00:33:50ZengFujita Medical SocietyFujita Medical Journal2189-72472189-72552018-02-01411510.20407/fmj.4.1_1Serum sclerostin concentration reflects bone turnover and glycation in men with type 2 diabetes mellitusEisuke TomatsuMegumi ShibataYasumasa YoshinoSahoko Sekiguchi-UedaAyako KakitaTakeshi TakayanagiMasaki MakinoNobuki HayakawaAtsushi SuzukiObjective: The risk of fracture is higher in people with than without diabetes. Because bone mineral density is not a good predictive marker of bone strength in people with diabetes, another surrogate is needed. Sclerostin is an inhibitor of bone formation and is secreted mainly by osteocytes. This study was performed to clarify how the serum sclerostin concentration reflects bone turnover in patients with type 2 diabetes. Methods: We measured the serum sclerostin concentration and other bone turnover markers in 49 patients with type 2 diabetes (26 men and 23 postmenopausal women). The osteo-sono assessment index was measured using ultrasonography at the calcaneus. Results: In men, the serum sclerostin concentration was significantly correlated with age, homocysteine, and pentosidine, reflecting an accumulation of advanced glycation end products in the bone. The multiple regression analysis showed that the serum pentosidine concentration was associated with the serum sclerostin concentration in men with type 2 diabetes. In contrast, sclerostin was not significantly correlated with pentosidine or other bone turnover markers in women with type 2 diabetes. Conclusions: The serum sclerostin concentration seems to increase in accordance with the accumulation of advanced glycation end products in patients with type 2 diabetes and might reflect the bone quality in men with diabetes.https://www.jstage.jst.go.jp/article/fmj/4/1/4_2017006/_pdf/-char/ensclerostintype 2 diabetesbone turnoverosteoporosis |
| spellingShingle | Eisuke Tomatsu Megumi Shibata Yasumasa Yoshino Sahoko Sekiguchi-Ueda Ayako Kakita Takeshi Takayanagi Masaki Makino Nobuki Hayakawa Atsushi Suzuki Serum sclerostin concentration reflects bone turnover and glycation in men with type 2 diabetes mellitus Fujita Medical Journal sclerostin type 2 diabetes bone turnover osteoporosis |
| title | Serum sclerostin concentration reflects bone turnover and glycation in men with type 2 diabetes mellitus |
| title_full | Serum sclerostin concentration reflects bone turnover and glycation in men with type 2 diabetes mellitus |
| title_fullStr | Serum sclerostin concentration reflects bone turnover and glycation in men with type 2 diabetes mellitus |
| title_full_unstemmed | Serum sclerostin concentration reflects bone turnover and glycation in men with type 2 diabetes mellitus |
| title_short | Serum sclerostin concentration reflects bone turnover and glycation in men with type 2 diabetes mellitus |
| title_sort | serum sclerostin concentration reflects bone turnover and glycation in men with type 2 diabetes mellitus |
| topic | sclerostin type 2 diabetes bone turnover osteoporosis |
| url | https://www.jstage.jst.go.jp/article/fmj/4/1/4_2017006/_pdf/-char/en |
| work_keys_str_mv | AT eisuketomatsu serumsclerostinconcentrationreflectsboneturnoverandglycationinmenwithtype2diabetesmellitus AT megumishibata serumsclerostinconcentrationreflectsboneturnoverandglycationinmenwithtype2diabetesmellitus AT yasumasayoshino serumsclerostinconcentrationreflectsboneturnoverandglycationinmenwithtype2diabetesmellitus AT sahokosekiguchiueda serumsclerostinconcentrationreflectsboneturnoverandglycationinmenwithtype2diabetesmellitus AT ayakokakita serumsclerostinconcentrationreflectsboneturnoverandglycationinmenwithtype2diabetesmellitus AT takeshitakayanagi serumsclerostinconcentrationreflectsboneturnoverandglycationinmenwithtype2diabetesmellitus AT masakimakino serumsclerostinconcentrationreflectsboneturnoverandglycationinmenwithtype2diabetesmellitus AT nobukihayakawa serumsclerostinconcentrationreflectsboneturnoverandglycationinmenwithtype2diabetesmellitus AT atsushisuzuki serumsclerostinconcentrationreflectsboneturnoverandglycationinmenwithtype2diabetesmellitus |